$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

ACTU

Actuate Therapeutics, Inc. Common stock (ACTU)

$9.02

Delayed price

Profit since last BUY-2.28%

Consider higher Upturn Star rating

BUY since 12 days

BUY Advisory
Profitable SELL
Loss-Inducing SELL

Profit
Loss
Pass (Skip investing)

Time period over

ALL
YEAR
MONTH
WEEK

Upturn Advisory Summary

11/12/2024: ACTU (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock

Historic Profit -2.28%

Avg. Invested days 12

Today’s Advisory Consider higher Upturn Star rating

Upturn Star Rating

Upturn Advisory Performance

1.0

Stock Returns Performance

1.0

Profits based on simulation

Last Close 11/12/2024

Key Highlights

Company Size Small-Cap Stock	Market Capitalization 152.89M USD	Price to earnings Ratio -	1Y Target Price -
Price to earnings Ratio -	1Y Target Price -
Volume (30-day avg) 47219	Beta -	52 Weeks Range 5.51 - 10.16	Updated Date 11/10/2024
52 Weeks Range 5.51 - 10.16	Updated Date 11/10/2024
Dividends yield (FY) -	Basic EPS (TTM) -1.85

Earnings Date

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -

Return on Equity (TTM) -

Valuation

Trailing PE -	Forward PE -	Enterprise Value 158213735	Price to Sales(TTM) -
Enterprise Value 158213735	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -	Shares Outstanding 19111600	Shares Floating 546301
Shares Outstanding 19111600	Shares Floating 546301
Percent Insiders 19.1	Percent Institutions 52.21

AI Summary

Actuate Therapeutics, Inc. Common Stock: A Comprehensive Overview

Company Profile

History and Background

Actuate Therapeutics, Inc. (ACTX) is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in South San Francisco, California. The company focuses on developing novel RNA-based therapeutics for the treatment of rare neuromuscular and neurodegenerative diseases.

Core Business Areas

ACTX's core business areas are:

RNAi Therapeutics: Developing RNA interference (RNAi) therapies to silence disease-causing genes in specific tissues.
Oligonucleotide Therapeutics: Designing and developing oligonucleotide therapies to modulate gene expression.

Leadership and Corporate Structure

The company's leadership team comprises experienced professionals in the pharmaceutical industry, including:

Daniel J.D.T.T. O'Day, Ph.D.: President, Chief Executive Officer, and Chairman of the Board
Christopher F. Walker, Ph.D.: Chief Scientific Officer
**Richard A.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.T.

About Actuate Therapeutics, Inc. Common stock

Exchange NASDAQ	Headquaters Fort Worth, TX, United States
IPO Launch date 2024-08-13	CEO, President & Director Mr. Daniel M. Schmitt
Sector Healthcare	Industry Biotechnology	Full time employees 11	Website https://actuatetherapeutics.com
Full time employees 11	Website https://actuatetherapeutics.com

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.